Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer
Sponsor: UNICANCER
Terminated
Inadequate toxicity
Other terminated trials from UNICANCER
Other Anal Cancer trials with similar outcome
A PHASE2 clinical study on Anal Cancer, this trial is terminated or withdrawn. The trial is conducted by UNICANCER and has accumulated 7 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
▶ Show 2 earlier versions
-
Jun 2018 — Mar 2020 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Brest, France , Caen, France , La Roche-sur-Yon, France , Lille, France , Limoges, France , Lyon, France , Montpellier, France , Nantes-Saint Herblain, France , Nice, France and 7 more locations